Today, at least one out of every six Americans, or 40 million people in the United States, suffer from one or more of the autoimmune and immune dysfunction diseases.

In response, chronically ill Americans spend over $300 billion per year for autoimmune syndrome treatments that often do not reduce their suffering or improve their health. That’s why PERQUE Integrative Health developed the patented LRA by ELISA/ACT tests and treatment plans, enabling thousands of physicians to quickly and precisely determine the hidden causes of many chronic conditions and help their patients find sustained relief.

The LRA makes it possible to examine the immune system’s general health by monitoring delayed hypersensitivity response of up to 487 common substances we’re exposed to everyday. These substances include foods, chemicals, minerals, molds, medications and more. Reactive items indicate triggers that are overburdening the immune system, opening the body up to a host of chronic diseases such as diabetes, obesity, heart disease, migraines, and fibromyalgia just to name a few.

The immune system is the gateway to a healthy body. If its overstressed and overworked then its unable to continually protect the body from harm, nor is it able to repair the damage harm has caused. If your patients suffer from chronic disease, fatigue, depression, pain, poor sleep, and/or stress, improving immune function may be the answer!

Three unique features of LRA by ELISA/ACT tests allow the tests to provide the most specific, reproducible, and accurate results of any delayed allergy testing method.

Comprehensive – The only tests that measure all 3 delayed allergy pathways at one time (Type II, Type III, and Type IV) and offering the most number of items for testing (up to 491).

Functional – Indentifying only symptom provoking reactive substances, not merely the presence of antibodies, which can be harmful or protective. When protective antibodies can’t be distinguished from harmful, the result is many false positive results.

Ex-Vivo – The unique ex-vivo system tests the lymphocytes as though they are still in the bloodstream being exposed to antigens.

To learn more visit LRA by ELISA/ACT Biotechnologies